These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Withdrawal-induced antihypertensive effect of vasopressin: role of the L-arginine/nitric oxide pathway.
    Author: Talom RT, McNeill JR.
    Journal: Can J Physiol Pharmacol; 1997 Jul; 75(7):812-7. PubMed ID: 9315348.
    Abstract:
    The role of the endothelium-derived relaxing factor (EDRF), nitric oxide (NO), in the withdrawal-induced antihypertensive phenomenon (WAP) of arginine vasopressin (AVP) was studied in conscious unrestrained rats implanted with femoral arterial catheters for the measurement of arterial blood pressure. Cessation of a 3-h intravenous infusion of AVP (20 ng.kg-1.min-1) was followed by a large and long-lasting fall in mean arterial blood pressure below preinfusion control values in spontaneously hypertensive rats (SHR; -47.5 +/- 6.4 mmHg; 1 mmHg = 133.3 Pa) but not in normotensive Wistar-Kyoto (WKY) and Sprague-Dawley (SD) control rats. Chronic treatment of normotensive SD rats with the NO synthesis inhibitor, N omega-nitro-L-arginine (L-NNA; 0.5 g.L-1 in drinking water for 2 weeks), resulted in sustained hypertension. Similar to the SHR model, a large fall in blood pressure (-37.8 +/- 7.7 mmHg) was observed in this model of hypertension following cessation of the AVP infusion. In SHR, inhibition of NO synthesis with L-NNA (0.05 g.L-1 in drinking water for 2 weeks) failed to attenuate the fall in blood pressure following withdrawal of AVP. Chronic treatment with the NO precursor, L-arginine (L-Arg; 1.25 g.L-1 in drinking water for 2 weeks), did not affect the amplitude or the time course of the WAP in SHR. The results indicate that the L-Arg/NO pathway is not essential to the expression of the WAP to AVP in the SHR.
    [Abstract] [Full Text] [Related] [New Search]